Introduction
Replicative immortality is an attribute of cancer cells governed by telomere maintenance (1) . Telomeres are repetitive nucleoprotein structures that protect chromosomal ends and shorten after each replicative cycle, playing important roles in genome stability and cancer prevention (2, 3) . To achieve replicative immortality, approximately 90% of human cancers reactivate telomerase -a holoenzyme responsible for elongating telomeres -through reexpression of the catalytic subunit telomerase reverse transcriptase (TERT) (4) .
Previous studies have identified 2 prevalent cancer-associated TERT promoter mutations (TPMs) causing a cytidine-to-thymidine change at genomic loci Chr5:1,295,228 (C228T) and 1,295,250 (C250T) as a genetic mechanism of TERT upregulation (5-9). However, TPMs do not prevent initial bulk telomere shortening at the time of malignant transformation and only act on cells with critically short telomeres to delay replicative senescence (10) , implying that TPMs alone are insufficient for cancer cells to exhibit the telomerase activity required for telomere length maintenance. Moreover, common tumor types, including breast, lung, prostate, colorectal, and hematological malignancies rarely exhibit TPMs (11) (12) (13) (14) (15) (16) yet display telomerase activity, supporting the idea that other undefined TERT-upregulating mechanisms must exist.
One mechanism that has not yet been thoroughly investigated is the epigenetic regulation of TERT. Previous seminal studies have reported an association between TERT promoter hypermethylation and elevated TERT expression in cancer (17, 18) , leading to our recent work, which uncovered this association in a specific region within the TERT promoter, termed upstream of the Replicative immortality is a hallmark of cancer cells governed by telomere maintenance. Approximately 90% of human cancers maintain their telomeres by activating telomerase, driven by the transcriptional upregulation of telomerase reverse transcriptase (TERT). Although TERT promoter mutations (TPMs) are a major cancer-associated genetic mechanism of TERT upregulation, many cancers exhibit TERT upregulation without TPMs. In this study, we describe the TERT hypermethylated oncological region (THOR), a 433-bp genomic region encompassing 52 CpG sites located immediately upstream of the TERT core promoter, as a cancer-associated epigenetic mechanism of TERT upregulation. Unmethylated THOR repressed TERT promoter activity regardless of TPM status, and hypermethylation of THOR counteracted this repressive function. THOR methylation analysis in 1,352 human tumors revealed frequent (>45%) cancer-associated DNA hypermethylation in 9 of 11 (82%) tumor types screened. Additionally, THOR hypermethylation, either independently or along with TPMs, accounted for how approximately 90% of human cancers can aberrantly activate telomerase. Thus, we propose that THOR hypermethylation is a prevalent telomerase-activating mechanism in cancer that can act independently of or in conjunction with TPMs, further supporting the utility of THOR hypermethylation as a prognostic biomarker. Figure 1A) . Methylation of the CpG sites within THOR was significantly increased in cancer cell lines compared with normal samples, with a mean methylation difference of 58% across THOR (P = 1.49 × 10 -9
; Figure 1A and Supplemental Figure 2 ). Unsupervised clustering based on the CpG methylation status within THOR clearly separated every TERT-expressing cancer cell line from normal samples ( Figure 1B) .
Increased THOR methylation across all 52 CpG sites was validated and confirmed in tumors from various tissues (n = 87; Figure 2A ), and unsupervised clustering separated 82% (71/87) of these tumors from normal samples ( Figure 2B ). To examine the transcription start site (UTSS) (19) . Several studies have reported frequent TERT promoter (UTSS) hypermethylation in various TERT-expressing cancer types (19) (20) (21) (22) (23) , suggesting an epigenetic mechanism of telomerase activation in multiple cancers. However, the boundaries and functional impact of this region on TERT promoter activity have not been examined in detail.
In this study, we used conventional and next-generation sequencing (NGS) to uncover TERT hypermethylated oncological region (THOR). Unmethylated THOR acts as a repressive element on TERT promoter activity, while methylation of THOR counteracts this repressive effect. Importantly, activating effects of TPMs on the TERT promoter are reduced when unmethylated THOR is present, implying that TPMs and THOR are 2 distinct TERT regulatory mechanisms. Finally, we found that THOR hypermethylation is a prevalent phenomenon in TERT-expressing tumor types, regardless of their TPM status.
Results and Discussion
We examined the methylation landscape of the TERT promoter, which included approximately 650 bp upstream of the transcrip- tion levels utilize other mechanisms for telomere maintenance, such as TPMs and the alternative lengthening of telomeres (ALT) pathway, respectively (24) . Furthermore, we compared matched normal control and tumor samples in a subset of lung (n = 32) and prostate (n = 67) cancers, in which 89.9% (89/99) of the tumors had higher THOR methylation levels than matched normal tissue samples by a median of 13.9% ( Figure 2D ), corroborating THOR methylation as a cancer-associated epigenetic event.
We assessed the prevalence of THOR methylation in cancer by dichotomizing tumor samples as hypomethylated or hypermethylated using a cutoff value of 16.1%, adding 2 SDs to the mean methylation of normal samples as previously described (see Methods) (19, 20) . All cancer types screened had a high prevalence (>45%) of THOR hypermethylation, with the exception of thyroid (3%) extent of THOR methylation in larger tumor cohorts, we tested and confirmed that 5 CpG sites (UTSS) (19) within THOR accurately represented the average THOR methylation (Supplemental Figure 3 ). Using these CpG sites, we screened 1,352 tumor and 80 normal samples from various tissues to assess THOR methylation in cancer ( Figure 2C ). The median THOR methylation of normal samples was 7.0%, with no samples exceeding 18.3%, while most adult cancer types exhibited significantly higher median THOR methylation (P < 0.05), with 91.4% of all tumors exceeding the median THOR methylation level of normal tissues. Of note, the low THOR methylation levels detected in thyroid cancers may be associated with their known lower malignant potential and better prognosis compared with other tumor types. Other tumor types such as skin and bone showing low and heterogeneous methyla- TERT core promoter resulted in a significant decrease in reporter gene expression compared with expression of the TERT core promoter alone in LN229 cells ( Figure 3A ) and in multiple cancer cell lines from different tissues (Supplemental Figure 4) . This region, which we defined as rTHOR (Chr5:1,295,395-1,295,743), is a functional region within THOR that represses TERT expression when unmethylated. We then tested the effect of rTHOR remethylation using a unique reporter gene plasmid completely devoid of CpG sites (pCpGfree-promoter-Lucia; InvivoGen Figure 5) . Hypermethylation of rTHOR resulted in a significant increase in reporter gene expression in LN229 cells and in 2 additional cancer cell lines (HeLa and HT1080) ( Figure 3B ), implying that methylation of THOR counteracts the repressive effect of rTHOR. Finally, we treated brain cancer and glioma stem cell lines, which harbor THOR hypermethylation and high TERT expression, with the demethylation agent decitabine, resulting in reduced THOR methylation and TERT expression (Supplemental Figure 6 ). In contrast, we found that TERT expression was not altered in normal embryonic stem cells lacking THOR hypermethylation (Supplemental Figure 6) after treatment with decitabine. These observations infer that canand skin (30%) cancers ( Figure 2E ). Interestingly, tumors in which TPMs are rarely observed (i.e., prostate, breast, blood, and colon cancers) (11, 12, 15, 16 ) displayed a higher prevalence of THOR hypermethylation compared with those in which TPMs are commonly found (i.e., skin, bladder, and brain cancers) (5, 8, 25) (Figure 2E) , suggesting that THOR hypermethylation may be a crucial TERT-activating mechanism in tumors without TPMs. Together, these observations highlight a potential cancer-associated mechanism of telomerase activation through THOR hypermethylation and suggest the usefulness of the THOR hypermethylation signature in differentiating normal and cancerous tissue.
To examine the role of THOR as a transcriptional regulatory element of TERT, we first performed 5′ truncation analysis of the TERT promoter using reporter gene constructs spanning both the TPM sites and THOR. We observed a continual increase in reporter gene expression in a cancer cell line (LN229) as THOR was gradually truncated from the 5′ end, with the pTERT-214 construct displaying peak promoter strength ( Figure 3A) . Further truncation of 82-bp (pTERT-132) resulted in an approximately 2-fold reduction of reporter gene expression, indicating that the minimal TERT core promoter is a region located up to 214 bp upstream of the TERT TSS, encompassing the TPM sites and the proximal 75 bp of THOR. Importantly, addition of repressive THOR (rTHOR) to the THOR or TPMs are distinct TERT regulatory regions. To investigate the functional repressive effect of unmethylated rTHOR in the context of TPMs, we compared reporter gene expression in the constructs pTERT(+rTHOR) and pTERT(−rTHOR), which contained the TERT core promoter with and without rTHOR, respectively, and in the presence and absence of C228T TPMs ( Figure 4A ). As expected, the addition of rTHOR to the TERT core promoter decreased promoter strength by an average of approximately 5-fold in all 3 cancer cell lines tested, while the C228T mutation resulted in an average increase of approximately 5-fold ( Figure 4A ). The addition of rTHOR to the C228T-mutated TERT core promoter effectively counteracted the activating effect of this mutation, and the activity was comparable to that of the WT TERT cer cells hypermethylate THOR to counteract the repressive effect of rTHOR and promote TERT upregulation. A high prevalence of THOR hypermethylation in tumor types that commonly harbor TPMs ( Figure 2E ) and the previous finding that TPMs alone are insufficient at preventing initial bulk telomere shortening at the time of malignant transformation (10) led us to investigate the relationship between THOR and TPMs. In contrast to the cancer-associated hypermethylation observed within THOR, the average DNA methylation of the CpG sites at the TPM locus (Chr5:1,295,225-1,295,263, GRCh37/hg19) was ubiquitously low (<10%) in normal tissue (0.8%), tumor samples (4.4%), and TERT-expressing cancer cell lines (9.2%) ( Figure 1A and Figure  2A ). This suggests that the genomic loci encompassing either (A) Normalized fold changes in TERT promoter activity are shown for the specified luciferase constructs, with the presence and absence of THOR and/or C228T TPM, in the glioblastoma cell line LN229 and the medulloblastoma cell lines ONS76 and UW228. *P < 0.05, **P < 0.01, and ***P < 0.001, by unpaired t test. (B) TERT expression (mean ± SD, black bars and dots, y axis) and average THOR methylation levels (red dots, y axis) are shown in human primary (1°) and cancer cell lines. TERT regulation-associated characteristics for all cell lines are shown below the graph. (C) Pie charts display the frequencies of TPMs and the THOR hypermethylation signature in TPM-common tumors (gliomas and melanomas) and TPM-independent tumors (prostate, lung, colon, and breast). (D) TERT expression (mean ± SD, black bars and dots, y axis) and THOR methylation levels (red dots, y axis) are shown in a subset of adult gliomas (n = 21). TERT regulation-associated characteristics for these samples are shown below the graph. jci.org Volume 129
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TERT core promoter and common TPM sites. We demonstrated that unmethylated rTHOR is a repressive element of the TERT promoter and that hypermethylation counteracts this effect, suggesting that cancer cells methylate THOR to upregulate TERT expression and activate telomerase. In addition, our study proposes 2 clinically relevant implications. First, unraveling the exact mechanism of THOR hypermethylation-driven TERT expression will uncover potential therapeutic targets for cancer treatment. Second, together with TPMs, the discovery of this TERTupregulating mechanism in cancer accounts for how approximately 90% of human cancers activate telomerase. Our findings provide biological insight into why tumors with THOR hypermethylation are associated with a poorer clinical outcome (19, 20, 22, 23) , further highlighting its value as a potential prognostic biomarker.
Methods
A complete description of the methods and statistical analysis is provided in the Supplemental Materials. An unsupervised clustering heatmap was created with a modified version of Methylation plotter (29) . NGS data are publicly available in the NCBI's Gene Expression Omnibus (GEO) database (GEO GSE120511 
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promoter without rTHOR. These findings indicate that THOR and TPMs are nonredundant but discrete regulatory mechanisms of TERT expression in cancer.
To explore the impact of these mechanisms on telomerase activation in cancer, we first examined whether they could co exist in 10 TERT-expressing cancer cell lines. All cell lines showed THOR hypermethylation and, importantly, 5 of the cell lines showed coexistence of the 2 TERT-activating mechanisms (Figure 4B) . However, we observed no significant difference in the levels of TERT expression between the cancer cell lines when TPMs were present or absent (Supplemental Figure 7) . This suggests that in certain cancers in which TPM is absent, other mechanisms such as THOR hypermethylation contribute to TERT expression. Second, we assessed the prevalence and coexistence of these mechanisms in cancer types in which TPMs are either frequently or rarely present ( Figure 4C) . In a cohort of cancers that commonly have TPMs (gliomas and melanomas, n = 396), we frequently (43%) observed TPMs and THOR hypermethylation together, while 45% of the tumors exhibited only 1 of the mechanisms. Meanwhile, in a cohort of cancers that lack TPMs (prostate, lung, breast, and colon cancers, n = 78), 90% of the tumors exhibited only THOR hypermethylation. Nonetheless, in both groups, the prevalence of THOR methylation, together with TPMs, reflected the overall frequency of telomerasedependent tumors (~90%). Third, we screened a subset of gliomas, which are tumors that exhibit heterogeneous telomere maintenance mechanisms including THOR hypermethylation, TPMs, and ALT (n = 21) ( Figure 4D ). Interestingly, 93.3% (14 of 15) of the TERT-expressing gliomas had THOR hypermethylation alone or with TPMs, while 83.3% (5 of 6) of the gliomas that lacked TERT expression were missing either one of the TERT-activating mechanisms but were primarily dependent on ALT for telomere maintenance. These observations highlight the role of THOR hypermethylation as one of the TERTupregulating mechanisms in cancer, either independently or in conjunction with TPMs.
Although we describe THOR hypermethylation as an additional TERT-upregulating mechanism, an understanding of its biological mechanism requires further investigation. A recent study has associated allele-specific hypomethylation and active histone marks (H3K4me2/3) in cancer cell lines that harbor TPMs (26) . In this case, THOR hypermethylation may act as a regulatory mechanism strictly through transcription factor binding, enabling TERT expression even in the allele without active histone marks. Cis-acting transcriptional repressors such as WT1 and MZF-2 are known to bind the genomic region within THOR (27) , but whether their binding is methylation sensitive requires further investigation. Another interesting aspect of THOR hypermethylation is that it may regulate other genes in the proximity to TERT that ultimately affect TERT expression. One example is the hTERT antisense promoter-associated (hTAPAS) noncoding RNA, whose promoter overlaps with the TERT promoter (28) . Last, to explore the coexistence and interplay between THOR hypermethylation and TPMs in more detail, single-cell-level analyses should be performed in the future.
In summary, this study defined THOR as a region of cancerassociated DNA hypermethylation that is located adjacent to the
